Small Molecule CDMO Market: Where Should Companies Invest as Pharmaceutical Outsourcing Expands?

The global small molecule CDMO market was valued at approximately USD 75.83 billion in 2025 and is projected to reach USD 135.75 billion by 2035, growing at a 6% CAGR. North America held 40.6% of the market in 2025, while Asia-Pacific is expected to record the fastest growth. APIs represented 63% of revenue, innovator drugs 57%, and oncology 35%.

Outsourcing Is Moving Toward More Complex Manufacturing

Pharmaceutical and biotechnology companies are increasingly outsourcing process development, API manufacturing, clinical supply and commercial production to reduce internal capital requirements and accelerate development. The trend is particularly relevant for complex small molecules, oncology drugs and high-potency APIs where specialized containment and manufacturing expertise are required.

The 2026 CDMO market shows a clear divide: large providers with late-stage and commercial manufacturing capabilities are performing better, while smaller CDMOs focused heavily on early-stage programs are facing pressure from tighter biotech financing.

API Manufacturing Remains the Core Opportunity

With APIs accounting for 63% of the market, capacity and technology for complex API development remain central to competitive positioning. Finished drug products, however, are expected to grow faster as pharmaceutical companies increasingly seek integrated services spanning formulation, clinical supply, packaging and commercial manufacturing.

This favors CDMOs capable of supporting a molecule across multiple stages instead of competing only on individual manufacturing steps.

Get a Free Sample: https://www.cervicornconsulting.com/sample/2995

Capacity Investments Are Increasing

Investment activity in 2026 shows that manufacturers are still expanding physical capacity for small molecules. Evonik is investing $100 million to upgrade its Tippecanoe, Indiana facility, adding production trains, equipment and laboratories for small-molecule APIs and advanced intermediates across development through commercial manufacturing.

Cambrex is progressing with a previously announced $120 million investment in a new large-scale API manufacturing facility in Iowa. The project is designed to add 140,000 liters of capacity and increase large-scale manufacturing capacity at the site by 20%.

These investments indicate that demand is increasingly favoring scalable commercial manufacturing rather than capacity designed only for early clinical programs.

Supply-Chain Diversification Is Creating Regional Opportunities

Pharmaceutical companies are reassessing manufacturing footprints amid supply-chain, geopolitical and trade considerations. India is gaining attention as an alternative manufacturing base, although its share of global CRDMO activity remains substantially below China's. Recent industry analysis estimates India's CRDMO market at only 2–3% of global share, compared with approximately 18–21% for China.

India's opportunity therefore depends less on low-cost manufacturing alone and more on building capabilities in complex APIs, high-potency compounds, process development and regulated-market supply.

Complex Molecules Could Improve Margins

Oncology accounted for 35% of the small molecule CDMO market in 2025, supported by investment in targeted therapies and kinase inhibitors. Complex APIs and HPAPIs require specialized containment, equipment and skilled personnel, raising entry barriers for less-capable manufacturers.

This creates a strategic opportunity for CDMOs that can combine chemistry expertise with high-containment manufacturing, analytical development and regulatory capabilities.

Integrated Services Are Becoming More Valuable

Pharma companies increasingly want partners that can manage multiple stages from process development through commercial supply. This reduces technology-transfer complexity and can improve continuity as a molecule progresses through clinical development.

Industry order inflows also improved during the second half of FY2026, supported by recovering biotech funding, normalization of inventories and increased outsourcing of late-stage programs.

AI and Digital Manufacturing Are Changing CDMO Economics

AI, automation, process analytical technology and digital twins are increasingly being applied to process optimization, equipment performance and manufacturing quality. Cervicorn notes that these technologies can reduce development risk by allowing manufacturing processes to be modeled and optimized before physical production.

For CDMOs, the value is not simply automation but the ability to shorten technology-transfer timelines, improve batch consistency and generate more usable process data.

Large Pharma Is Also Expanding Internal Capacity

The outsourcing market is growing alongside major pharmaceutical companies' investments in domestic manufacturing. Bristol Myers Squibb announced a $2.3 billion Houston manufacturing site in August 2026 as part of a broader $40 billion U.S. investment commitment. The facility is designed to manufacture small-molecule medicines as well as biologics and antibody-drug conjugates, with flexibility for future expansion.

For CDMOs, this means competition will come not only from other outsourcing providers but also from pharmaceutical companies selectively bringing strategic production capabilities closer to their own networks.

Where Should Companies Invest?

The strongest opportunities are emerging around complex APIs, HPAPIs, oncology manufacturing, integrated development-to-commercial services, high-containment facilities, advanced process technologies, AI-enabled manufacturing and regional supply-chain diversification.

For CDMOs, expanding capacity alone may not be enough. The stronger investment case is likely to come from specialized capabilities that are difficult to replicate and can support molecules through multiple development stages.

The Key Business Decision

The small molecule CDMO market is becoming less about manufacturing volume alone and more about technical complexity, regulatory reliability, capacity flexibility and end-to-end support.

Companies evaluating investments should therefore assess whether new capacity can attract late-stage and commercial programs, support complex molecules, meet stringent regulatory requirements and remain competitive as pharmaceutical companies diversify manufacturing across regions.

Explore the Full Market Report: https://www.cervicornconsulting.com/small-molecule-cdmo-market